摘要
Abstract
Objective:To investigate the clinical effect of Recombinant Human Endostatin combined with transcatheter arterial chemoembolization in patients with primary hepatic carcinoma.Method:From December 2012 to December 2014,120 patients with primary liver cancer in our hospital were randomly divided into the control group and the observation group,each group had 60 cases.The control group was treated with TACE,the observation group was treated with Recombinant Human Endostatin combined with TACE.The clinical efficacy, immune function and quality of life in two groups were compared.Result:The clinical effective rate of the observation group was 71.67% and the disease control rate was 90.00%,were significantly higher than 45.00% and63.33% of the control group,the differences were statistically significant(P<0.01).The levels of CD3+、CD4+、CD4+/CD8+ were decreased compared with before treatment in the control group,while the levels of CD3+、CD4+、CD4+/CD8+ were higher than before treatment in the observation group,and the observation group was higher than those of the control group,the differences were statistically significant(P<0.05). The control group IgA,IgG, IgM decreased than before treatment and the observation group was higher than before treatment,the observation group was higher than the control group,the differences were statistically significant(P<0.05).The survival rate of the observation group was 86.67%,higher than 65.00% of the control group,the difference was statistically significant(P<0.05).Conclusion:TACE combined with Recombinant Human Endostatin can improve therapeutic effect of patients with primary liver cancer,enhance the immune ability and improve the quality of life.关键词
重组人血管内皮抑制素/肝动脉化疗栓塞/原发性肝癌Key words
Recombinant Human Endostatin/Transcatheter arterial chemoembolization/Primary hepatic carcinoma
